Reference ยท 453 compounds
Half-Life Reference
How long each compound stays active, placed on one stretched scale from minutes to weeks. Half-life is the time for the amount in the body to drop by half. After roughly four to five half-lives, a compound is basically gone. Compounds with no published number are marked unknown. We do not drop them or guess.
Plate 13
Decay curve
Half-life, not a cycle
236
With a published half-life
~5 HL
About 97% gone after 5 half-lives
Sort
Band
- ThymopentinImmuneUltra-shortModerateVery short (~30 seconds native)
- GLP-1MetabolicUltra-shortLimited~1-2 minutes (native)
- VIPHealing & RecoveryUltra-shortLimited~1-2 minutes (native)
- SomatostatinGrowth HormoneUltra-shortAnimal or lab only~1-3 minutes (native)
- GonadorelinHormoneUltra-shortModerate~2-4 minutes
- OxytocinHormoneUltra-shortModerate~1-6 minutes
- GalaninNootropic & CNSUltra-shortLimitedAbout 3.7 minutes in plasma, measured directly during intravenous infusion of human galanin in healthy volunteers, and similar to that of porcine galanin. This is a peptide cleared in single-digit minutes.
- GLP-2MetabolicUltra-shortAnimal or lab only~7 minutes (native)
- GlucagonMetabolicUltra-shortModerate~8-18 minutes
- SermorelinGrowth HormoneUltra-shortModerate~10-20 minutes
- VasopressinHormoneUltra-shortModerate~10-20 minutes
- NeurotensinNootropic & CNSUltra-shortLimitedVery short in circulation, which is characteristic of small neuropeptides cleared rapidly by peptidases. No specific measured human figure is asserted here because none was resolved in this pass.(about)
- CurcuminAntioxidantUltra-shortModerateVery short for unformulated curcumin, with extensive first-pass conjugation and plasma concentrations often near the limit of detection after ordinary doses. Enhanced formulations report multi-fold increases in exposure, and those multiples are formulation-specific rather than a property of curcumin.(about)
- InsulinMetabolicUltra-shortStrongAbout 20 minutes intravenously for regular human insulin
- NemifitideNootropic & CNSUltra-shortModerate15 to 30 minutes
- VosoritideGrowth HormoneUltra-shortLimitedRoughly 20 to 30 minutes, very short, which is why it requires daily subcutaneous injection despite being engineered for stability against neutral endopeptidase.
- BPC-157Healing & RecoveryUltra-shortLimitedUnder 30 minutes in plasma in a two-person pilot; the animal literature describes effects lasting hours to days.
- SemaxNootropic & CNSUltra-shortModerateShort (minutes); intranasal use(about)
- SelankNootropic & CNSUltra-shortModerateShort (minutes); intranasal use(about)
- EpitalonAnti-agingUltra-shortModerateShort (minutes)(about)
- GlutathioneAntioxidantUltra-shortLimitedMinutes (plasma)(about)
- Melanotan IMelanocortinUltra-shortModerate~30 minutes (implant provides sustained release)
- Kisspeptin-10HormoneUltra-shortLimitedShort (minutes)(about)
- GhrelinGrowth HormoneUltra-shortLimited~30 minutes
- DSIPNootropic & CNSUltra-shortLimitedShort (minutes)(about)
- Alpha-MSHMelanocortinUltra-shortAnimal or lab onlyShort (minutes)(about)
- Alpha-Lipoic AcidAntioxidantUltra-shortLimited~30 minutes
- MGFMuscle & PerformanceUltra-shortPreliminaryMinutes (native peptide)(about)
- IGF-1 DESMuscle & PerformanceUltra-shortAnimal or lab onlyMinutes(about)
- Ac-SDKPHealing & RecoveryUltra-shortAnimal or lab onlyMinutes (ACE cleavage)(about)
- BrimapitideNootropic & CNSUltra-shortModerateAbout 20 to 40 minutes (intravenous, healthy volunteers)
- Ketone estersMetabolicUltra-shortLimitedBlood beta-hydroxybutyrate rises within roughly 30 minutes and returns toward baseline within a few hours, so effects are acute and require repeated dosing to sustain.
- TestosteroneHormoneUltra-shortModerateFree testosterone itself clears in minutes to hours. What determines dosing is the ester: cypionate and enanthate run roughly eight days, propionate under a day, and undecanoate several weeks. The ester pages cover what that means in practice.(about)
- ExosomesHealing & RecoveryUltra-shortModerateNot meaningfully described. Systemically administered vesicles are cleared from circulation within minutes to hours, mostly by liver and spleen, which is one reason the strongest human evidence involves local application rather than infusion.(about)
- BeinaglutideMetabolicUltra-shortModerateVery short, because it is the unmodified human hormone. It is injected three times daily before meals, and in the phase one study plasma concentrations peaked within roughly fifteen minutes and then declined.(about)
- Neuropeptide YNootropic & CNSUltra-shortLimitedVery short. NPY is cleared from plasma within minutes, and dipeptidyl peptidase-4 cleaves it into a fragment with different receptor preferences rather than simply destroying it. No single agreed circulating figure is asserted here; the PTSD trial used an intranasal route specifically to get around the problem.(about)
- CarnosineAntioxidantUltra-shortModerateVery short in plasma. Circulating carnosinase hydrolyses an oral dose within minutes, which is the central pharmacokinetic fact about this compound.(about)
- Wolverine blendHealing & RecoveryUltra-shortPreliminaryNot defined for the blend, and the components differ. A systematic review reports BPC-157 as hepatically metabolised with a half-life under 30 minutes and renal clearance.
- Semax / SelankNootropic & CNSUltra-shortModerateNot one number, and neither component has published nasal pharmacokinetics in the West. Both are described as clearing within minutes.(about)
- Angiotensin IIHormoneUltra-shortModerateLess than one minute(about)
- TesamorelinGrowth HormoneUltra-shortStrong~26-38 minutes
- GHRP-6Growth HormoneUltra-shortLimited~15-60 minutes
- GHRP-2Growth HormoneUltra-shortModerate~30-60 minutes
- PramlintideMetabolicUltra-shortModerate~48 minutes
- AmylinMetabolicUltra-shortModerateNative amylin is short-lived in circulation. For the approved analogue pramlintide the label gives roughly 48 minutes.
- Sodium phenylbutyrateLongevityUltra-shortModerateRoughly 0.8 hours for the parent compound, which is rapidly converted to phenylacetate and then conjugated, requiring multiple daily doses clinically.
- HexarelinGrowth HormoneUltra-shortModerate~55 minutes
- GHK-CuHealing & RecoveryShortLimitedShort (topical use)(about)
- ThymalinImmuneShortModerateShort(about)
- Melanotan IIMelanocortinShortStrong~1 hour
- FOXO4-DRIAnti-agingShortLimitedShort(about)
- NAD+LongevityShortLimitedShort(about)
- NMNLongevityShortLimitedShort(about)
- MOTS-cLongevityShortLimitedShort(about)
- HumaninLongevityShortLimitedShort(about)
- AOD-9604MetabolicShortLimitedShort(about)
- HGH Fragment 176-191MetabolicShortAnimal or lab onlyShort(about)
- AdipotideMetabolicShortAnimal or lab onlyShort(about)
- FollistatinMuscle & PerformanceShortLimitedShort (protein)(about)
- ARA-290Healing & RecoveryShortLimitedShort(about)
- KPVHealing & RecoveryShortAnimal or lab onlyShort(about)
- LarazotideHealing & RecoveryShortModerateShort (acts locally in the gut)(about)
- LL-37ImmuneShortModerateShort(about)
- DihexaNootropic & CNSShortAnimal or lab onlyShort(about)
- P21Nootropic & CNSShortAnimal or lab onlyShort(about)
- PE-22-28Nootropic & CNSShortAnimal or lab onlyShort(about)
- NoopeptNootropic & CNSShortLimitedShort(about)
- GHRP-1Growth HormoneShortAnimal or lab onlyShort(about)
- 5-Amino-1MQMetabolicShortAnimal or lab onlyShort(about)
- DavunetideNootropic & CNSShortModerateShort(about)
- FGLNootropic & CNSShortAnimal or lab onlyShort(about)
- PinealonNootropic & CNSShortLimitedShort(about)
- ThymogenImmuneShortPreliminaryShort(about)
- ThymulinImmuneShortAnimal or lab onlyShort(about)
- VilonAnti-agingShortAnimal or lab onlyShort(about)
- CardiogenAnti-agingShortNoneShort(about)
- TeriparatideHormoneShortModerate~1 hour
- AbaloparatideHormoneShortModerate~1 hour
- CalcitoninHormoneShortPreliminary~1 hour
- ArgirelineCosmeticShortModerateTopical (surface)(about)
- MatrixylCosmeticShortModerateTopical (penetrates surface)(about)
- SNAP-8CosmeticShortLimitedTopical (surface)(about)
- Nicotinamide RibosideLongevityShortLimitedShort(about)
- SpermidineLongevityShortModerateShort(about)
- Calcium AKGLongevityShortPreliminaryShort(about)
- GlyNACAntioxidantShortLimitedShort (both components)(about)
- SLU-PP-332Muscle & PerformanceShortAnimal or lab onlyShort(about)
- RLS-1496Anti-agingShortPreliminaryTopical application(about)
- BRPMetabolicShortAnimal or lab onlyShort; no human pharmacokinetics(about)
- PTD-DBMCosmeticShortAnimal or lab onlyNot established (topical)(about)
- BAM15MetabolicShortAnimal or lab onlyShort in rodents; unknown in humans(about)
- AICARMuscle & PerformanceShortModerateShort(about)
- SR9009MetabolicShortAnimal or lab onlyShort; poor oral bioavailability(about)
- AHK-CuCosmeticShortAnimal or lab onlyNot established (topical)(about)
- B7-33Healing & RecoveryShortAnimal or lab onlyShort(about)
- Orexin-ANootropic & CNSShortLimitedShort(about)
- TaurineLongevityShortModerateAbout 1 hour in plasma
- GIPMetabolicShortLimitedShort. Inactivated by dipeptidyl peptidase-4. No single agreed numeric half-life for intact human GIP resolved in our sources, so none is asserted here.(about)
- OxyntomodulinMetabolicShortLimitedShort. Rapidly degraded by dipeptidyl peptidase-4. No single verified numeric half-life is asserted here because our sources do not agree on one.(about)
- EcdysteroneMuscle & PerformanceShortModerateShort, with oral bioavailability generally reported as poor, which is the main obstacle to translating cell and animal results. No single agreed human figure was resolved in the sources loaded.(about)
- IcatibantHormoneShortModerateAbout 1.4 hours
- L-leucineMuscle & PerformanceShortLimitedRoughly 1 to 2 hours in plasma after an oral dose, which is why leucine is described as producing a pulse of signalling rather than sustained exposure.
- OctreotideHormoneShortModerate~1.7 hours (long-acting depot lasts weeks)
- IpamorelinGrowth HormoneShortModerate~2 hours
- Thymosin Alpha-1ImmuneShortStrong~2 hours
- Thymosin Beta-4Healing & RecoveryShortStrong~2 hours
- TeduglutideMetabolicShortLimited~2 hours
- FisetinLongevityShortLimited~1-3 hours
- AcarboseLongevityShortPreliminaryAbout 2 hours; acts locally in the gut with minimal systemic absorption
- SimvastatinLongevityShortStrongAbout 2 hours for the parent drug, though the effect on cholesterol synthesis outlasts plasma exposure, which is why it is dosed once daily.
- SulforaphaneAntioxidantShortModerateRoughly 2 hours in plasma after an oral dose, with most urinary metabolite excretion complete within about a day.
- ExenatideMetabolicShortStrong~2.4 hours (immediate release)
- ElamipretideAnti-agingShortModerate~2-3 hours
- DesmopressinHormoneShortModerate~1.5-3.5 hours
- PT-141MelanocortinShortStrong~2.7 hours
- LixisenatideMetabolicShortStrong~3 hours
- LeuprolideHormoneShortModerate~3 hours (depot lasts months)
- Urolithin AMuscle & PerformanceShortLimitedSeveral hours(about)
- VerteporfinHealing & RecoveryShortPreliminaryHours(about)
- CreatineMuscle & PerformanceShortModerateAbout 3 hours in plasma; muscle stores deplete over roughly 4 to 6 weeks after stopping
- Collagen peptidesCosmeticShortLimitedPeptide fragments cleared within hours; any structural effect would be over months(about)
- MethotrexateImmuneShortStrongThree to ten hours at low doses, longer at high doses and in renal impairment, which is the main determinant of its toxicity.(about)
- Dimethyl fumarateAntioxidantShortLimitedVery short as the parent compound, which is rapidly hydrolysed to monomethyl fumarate, the active metabolite, with a half-life of roughly one hour.(about)
- HydralazineLongevityShortStrongRoughly three to seven hours, and it varies substantially with acetylator genotype, so slow acetylators get much higher exposure from the same dose.(about)
- MetreleptinHormoneShortPreliminaryRoughly three to four hours after subcutaneous injection, which is why it is dosed daily.(about)
- SupaglutideMetabolicShortModerateLong enough for once weekly dosing, and a biweekly schedule has been tested in a randomised trial. In rhesus monkeys the subcutaneous half-life was reported at about forty hours; no human figure is asserted here.(about)
- MCT oilMetabolicShortModerateNot applicable to the oil itself. The medium-chain fatty acids are absorbed directly into the portal vein and oxidised rapidly, with the resulting ketone rise measured in hours rather than days.(about)
- ISRIBAnti-agingShortAnimal or lab onlyNot established in humans. Reported in mice as a matter of hours after a single dose.(about)
- NiacinLongevityShortStrongUnder an hour for immediate-release nicotinic acid. Extended-release formulations were built specifically to stretch that out and blunt the flush, and the dose is not interchangeable between forms.(about)
- ApigeninAntioxidantShortPreliminaryNo reliable human elimination half-life has been established. In the parsley bioavailability study, plasma apigenin peaked around seven hours after an oral bolus and had fallen below the detection limit within about a day.(about)
- RuxolitinibAnti-agingShortModerateAbout 3 hours.
- IdebenoneAntioxidantShortModerateShort in plasma, a matter of hours, with extensive first-pass metabolism to conjugated metabolites.(about)
- CJC-1295 / IpamorelinGrowth HormoneShortLimitedNot one number. The two components clear on completely different timescales, one within a few hours and the other over about a week.(about)
- Tesamorelin / IpamorelinGrowth HormoneShortStrongNot one number. Both components clear within hours, but not at the same rate, and neither has been measured in the presence of the other.(about)
- NAD+ / B ComplexLongevityShortLimitedNot one number. The two parts leave the body on completely different timescales, one within hours and the other held in the liver for months.(about)
- Sermorelin / GHRPGrowth HormoneShortLimitedNot one number. Both components clear within roughly an hour, the secretagogue somewhat more slowly than the GHRH fragment, and neither has been measured in the presence of the other.(about)
- Vitamin DLongevityShortStrongCirculating 25-hydroxyvitamin D has a half-life of roughly two to three weeks, which is why a level is reasonably stable and why loading doses persist. The active 1,25-dihydroxy form turns over in hours.(about)
- SomatropinGrowth HormoneShortLimited~3-4 hours (subcutaneous)
- GoserelinHormoneShortPreliminary~4 hours (implant lasts 1-3 months)
- DasatinibLongevityShortLimited~3-5 hours
- EGCGAntioxidantShortStrongRoughly 3 to 5 hours in plasma for free EGCG after an oral dose, with conjugated forms persisting longer.
- NicotinamideLongevityShortModerateAbout 4 hours in plasma, which is why the skin cancer trials dosed it twice a day rather than once.
- LeptinMetabolicShortModerate3.8 to 4.7 hours
- DanazolHormoneShortLimitedAbout 4 to 5 hours after a single dose, with longer estimates reported on repeated dosing.
- ZiconotideNootropic & CNSShortModerateAbout 4.6 hours in cerebrospinal fluid after intrathecal administration, with a reported range of roughly 2.9 to 6.5 hours. Clearance from the cerebrospinal fluid approximates the normal turnover rate of that fluid.
- NACAntioxidantShortLimited~5-6 hours
- Methylene BlueAntioxidantShortLimited~5 to 6 hours (oral)
- MeclizineLongevityShortAnimal or lab onlyRoughly 5 to 6 hours in humans, which is why it is dosed once or twice daily for motion sickness.
- LamivudineAnti-agingMediumLimitedRoughly 5 to 7 hours in plasma; the active intracellular triphosphate persists considerably longer.
- MetforminLongevityMediumModerate4 to 9 hours (plasma), longer in erythrocytes
- RilmenidineLongevityMediumPreliminaryAbout 8 hours.
- ErythropoietinHormoneMediumStrong4 to 13 hours
- ResveratrolLongevityMediumModerateAbout 9 hours for resveratrol plus its sulfate and glucuronide conjugates after an oral dose; free parent compound is cleared far faster
- OxandroloneMuscle & PerformanceMediumPreliminaryRoughly 9 hours, short for an androgen, which is why it is dosed once or twice daily rather than weekly.
- StanozololMuscle & PerformanceMediumPreliminaryRoughly 9 hours for the oral form, so it is dosed daily. An injectable aqueous suspension also exists with different kinetics.
- AmbroxolAnti-agingMediumLimitedAbout 10 hours.
- SetmelanotideMelanocortinMediumLimited~11 hours
- EnalaprilLongevityMediumStrongAbout 11 hours (enalaprilat, effective half-life for accumulation)
- EmpagliflozinMetabolicMediumStrongAbout 12 hours.
- LiraglutideMetabolicMediumStrong~13 hours
- NattokinaseLongevityMediumStrongNot established in humans; a pharmacokinetic pilot found intact enzyme peaks in serum around 13 hours after a single oral dose
- EnlicitideMetabolicMediumStrongEffective half-life around 14 hours; terminal half-life considerably longer
- L-CarnitineMuscle & PerformanceMediumLimited~15 hours
- DHEAHormoneMediumModerateShort for DHEA itself, a few hours. The sulphate form circulates far longer, around 10 to 20 hours, and is what laboratories usually measure.
- MinocyclineLongevityMediumModerateAbout 16 hours, which is long for a tetracycline and is why it is dosed once or twice daily.
- Mycophenolic acidImmuneMediumModerateRoughly 16 to 18 hours for mycophenolic acid after administration as mycophenolate mofetil, with enterohepatic recirculation producing a secondary peak.
- AstaxanthinAntioxidantMediumAnimal or lab onlyRoughly 15 to 20 hours in humans, with absorption substantially improved by dietary fat.
- MifepristoneHormoneMediumModerateRoughly 18 hours in the terminal phase, after a slower initial distribution, so once-daily dosing is used clinically.
- QuercetinLongevityMediumLimited~11-28 hours
- PioglitazoneMetabolicMediumStrongThree to seven hours for the parent compound, with active metabolites extending to roughly 16 to 24 hours, which supports once-daily dosing.
- OveporextonNootropic & CNSMediumModerateApproximately 23.2 hours
- MK-677Growth HormoneLongLimited~24 hours
- ACE-031Muscle & PerformanceLongLimitedDays (fusion protein)(about)
- Vitamin B12MetabolicLongLimitedDays to weeks (stored in liver)(about)
- EnobosarmMuscle & PerformanceLongModerate~24 hours (once-daily oral)
- CardarineMetabolicLongPreliminary~24 hours (reported)
- Ursodeoxycholic acidLongevityLongLimitedRoughly three and a half to six days for the bile acid pool, with extensive enterohepatic recirculation, so steady state takes weeks.(about)
- TrametinibLongevityLongStrongRoughly four to five days, which is unusually long for a small-molecule kinase inhibitor and means exposure accumulates over the first weeks.(about)
- Testosterone blendsHormoneLongLimitedNot a single figure, which is the defining feature. A blend releases across a range spanning roughly a day for the shortest ester to a couple of weeks for the longest, so there is no one half-life to reason with.(about)
- BetaineMetabolicLongModerateBetaine is cleared slowly enough that once-daily dosing raises serum levels across the day, but a precise human plasma half-life is not asserted here.(about)
- Low-dose lithiumLongevityLongModerateRoughly 24 hours in plasma for lithium in healthy adults, and longer in older people and in reduced kidney function.
- Relaxin-2HormoneLongStrongShort enough that both confirmatory trials gave it as a continuous intravenous infusion over two days rather than as injections. No single agreed circulating figure for the native hormone is asserted here; the long-acting fusion proteins now in development exist specifically to solve that problem.(about)
- MecaserminGrowth HormoneLongLimitedShort, and shorter in the patients it treats. The circulating hormone is normally bound almost entirely to its binding protein and the acid-labile subunit, which extends its persistence enormously; in severe primary deficiency those binding proteins are low, so the administered hormone is cleared faster. This is why the approved product is injected twice daily with food rather than once a day.(about)
- MIB-626LongevityLongModerateThe pharmacokinetic trial measured blood NMN and NAD exposure rather than a clean elimination half-life. NMN itself clears quickly and very little unmodified NMN was recovered in urine, while the downstream NAD rise built gradually over days and peaked late in the dosing period.(about)
- Kisspeptin-54HormoneLongModerateNo human pharmacokinetic curve is asserted here because none was resolved in this pass. What the trials report instead is the downstream effect: a single subcutaneous dose produces a luteinising hormone surge the investigators describe as lasting roughly half a day, which is a pharmacodynamic duration and not a plasma half-life.(about)
- BerberineMetabolicLongModerateSystemically short with very low oral bioavailability, under 1%, which is why it is dosed two or three times a day with meals. Active metabolites including berberrubine circulate longer than the parent compound.(about)
- IGF-1 LR3Growth HormoneLongPreliminary~20-30 hours
- RusfertideHormoneLongModerate28.6 hours (mean, plus or minus 11.3 hours, from the FDA label)
- HCGHormoneLongLimited~24-36 hours
- EverolimusLongevityLongStrongRoughly 30 hours, substantially shorter than rapamycin's 60 or more, which is the practical reason it was chosen for intermittent low-dose geroscience trials.
- CoQ10AntioxidantLongModerateRoughly 33 hours after oral dosing. Absorption is poor and highly dependent on fat co-ingestion, which is why dosing with a meal containing fat is the standard instruction.
- CetrorelixHormoneLongModerate~5-63 hours (formulation dependent)
- ClenbuterolMuscle & PerformanceLongLimitedAbout 35 hours in plasma in healthy volunteers, which is long for a beta-2 agonist and is why effects and detection both persist for days.
- OrforglipronMetabolicLongStrong~29-49 hours
- Ginsenoside Rg3LongevityLongLimited32 to 54 hours
- VisepegenatideMetabolicLongModerateAbout 55 hours.
- RapamycinLongevityLongLimited~60 hours
- Omega-3LongevityLongStrongRoughly 2 to 3 days for plasma phospholipid EPA and DHA. Red cell membrane incorporation, which is what an omega-3 index measures, is far slower and takes about 120 days to reach steady state and about the same to wash out, so retest the index at four months rather than at one.
- Azithromycin and roxithromycinAnti-agingLongModerateAbout 68 hours for azithromycin, which is unusually long; roxithromycin clears considerably faster.
- KN069MetabolicLongLimitedRoughly 900 to 1,100 hours for total drug, which is 37 to 46 days, measured across the 12 to 90 mg dose range. Among the longest on this site, and the reason a single dose acted for up to 133 days.
- TirzepatideMetabolicLongStrong~5 days
- DulaglutideMetabolicLongStrong~5 days
- AlbiglutideMetabolicLongStrongAbout 5 days (FDA label)
- EfpeglenatideMetabolicLongStrong~5-6 days
- RetatrutideMetabolicLongStrong~6 days
- SurvodutideMetabolicLongStrong~6 days
- MazdutideMetabolicLongStrong~5-7 days
- Modified GRF 1-29Growth HormoneLongLimitedNot measured in humans for this compound. For scale, native GRF 1-29 is cleared within minutes, while the albumin-bound DAC version was measured at about 6 days in healthy adults.
- SemaglutideMetabolicLongStrong~7 days
- CJC-1295Growth HormoneLongLimited~6-8 days (DAC version)
- CagrilintideMetabolicLongStrong~7 days
- ErgothioneineAntioxidantLongPreliminaryLong (retained in tissues)(about)
- CagriSemaMetabolicLongStrong~7 days (weekly dosing)
- EcnoglutideMetabolicLongModerateLong-acting(about)
- EfocipegtrutideMetabolicLongModerateLong-acting(about)
- BofanglutideMetabolicLongModerateAbout 7 days.
- NMNHLongevityLongLimitedNo human pharmacokinetic study has been published, so no half-life in people can be stated. In mice the whole-blood NAD rise was described as rapid and sustained, which is a downstream metabolite measurement rather than clearance of the compound.(about)
- BromantaneNootropic & CNSLongModerateNo published human pharmacokinetic study was located in this pass. Claims of a long duration of action circulate widely and none of them traces to a measured human plasma curve.(about)
- Testosterone enanthateHormoneVery longLimitedRoughly 7 to 8 days, close enough to cypionate that the two behave alike in practice.
- TesofensineMetabolicVery longLimited~8 days
- Testosterone cypionateHormoneVery longModerateRoughly 8 days. That single number is the argument: at an eight-day half-life, a fortnightly interval spans nearly two half-lives, so levels at the end of the cycle are a fraction of the peak.
- PegcetacoplanImmuneVery longStrongAbout 8.6 days as the median effective half-life in paroxysmal nocturnal haemoglobinuria. Reported as longer in C3 glomerulopathy and shorter after intravitreal injection, where the geometric mean is roughly four and a half days.
- Nandrolone decanoateMuscle & PerformanceVery longLimitedRoughly 6 to 12 days as the decanoate ester, so it is dosed weekly or less often. Detectable metabolites persist far longer, which matters for anyone subject to drug testing.
- MariTideMetabolicVery longLimitedWeeks (monthly dosing)(about)
- BimagrumabMetabolicVery longModerateWeeks (antibody)(about)
- PegozaferminMetabolicVery longLimitedWeekly or every-two-week dosing(about)
- MibavademabMetabolicVery longLimitedNot asserted. Pharmacokinetics were characterised in a first-in-human study; no half-life figure was resolved in the sources loaded. Monoclonal antibodies of this class generally clear over weeks.(about)
- Anti-IL-11LongevityVery longAnimal or lab onlyNot asserted. Depends on the specific antibody, and no figure for a human agent in this class was resolved in the sources loaded. Monoclonal antibodies generally clear over weeks.(about)
- NRPTLongevityVery longModerateNot a single molecule, so a single half-life does not apply. The relevant kinetics are those of nicotinamide riboside and pterostilbene separately, and the measured effect in the trials is the downstream whole blood NAD rise, which built over weeks and persisted for the duration of dosing.(about)
- StamulumabMuscle & PerformanceVery longModerateNot asserted. No half-life figure was resolved for this antibody in the sources loaded. Antibodies of this class generally clear over weeks.(about)
- BerobenatideMetabolicVery longLimited~15 days (~360 hours)
- MET-233iMetabolicVery longLimited~19 days
- LanreotideHormoneVery longLimitedRoughly 23 to 30 days from the prolonged-release depot formulation, so it is dosed every four weeks by deep subcutaneous injection.
- TriptorelinHormoneVery longStrongGoverned by release from the depot rather than by plasma clearance. Suppression is maintained across the labelled injection interval, and the one, three and six month formulations differ in how long that interval is.(about)
- Botulinum toxin type ACosmeticVery longStrongNot a meaningful plasma measure. The drug acts locally and is not detectable systemically at therapeutic doses; the duration of effect reflects how long it takes nerve terminals to regenerate, which is typically several months.(about)
- DegarelixHormoneVery longModerateAbout 53 days terminal, driven by slow release from the subcutaneous depot.
- (R/S)-1,3-ButanediolLongevityUnknownLimitedvaries, not on a fixed pointNot reported
- 17-alpha-estradiolLongevityUnknownAnimal or lab onlyvaries, not on a fixed pointNot asserted for the mouse dosing regimen. It is fed in the diet in these studies, so exposure is continuous rather than pulsed.
- 17-DMAGLongevityUnknownLimitedvaries, not on a fixed pointNot reported
- 25-HydroxycholesterolLongevityUnknownPreliminaryvaries, not on a fixed pointNot reported
- 5-amino-1MQ with SLU-PP-332MetabolicUnknownAnimal or lab onlyvaries, not on a fixed pointNot defined for the blend, and not published for either component in people.
- ABT-737LongevityUnknownPreliminaryvaries, not on a fixed pointNot reported
- AdiponectinMetabolicUnknownPreliminaryvaries, not on a fixed pointNot reported
- AdropinMetabolicUnknownPreliminaryvaries, not on a fixed pointNot established in humans. No one has administered it, so there is no human pharmacokinetic study to draw on.
- AHK-Cu with GHK-CuCosmeticUnknownLimitedvaries, not on a fixed pointNot applicable to a serum left on the skin, and no penetration or clearance data exists for either component in this form.
- AleniglipronMetabolicUnknownLimitedvaries, not on a fixed pointOnce-daily oral dosing
- Alpha-2-MacroglobulinLongevityUnknownLimitedvaries, not on a fixed pointNot reported
- Alpha-ketobutyrateLongevityUnknownPreliminaryvaries, not on a fixed pointNot characterised in humans. It is a fast-turnover intermediate of amino acid metabolism rather than a compound with a published supplemental pharmacokinetic profile.
- AmycretinMetabolicUnknownModeratevaries, not on a fixed pointSupports weekly (injectable) dosing
- Angiotensin-(1-7)HormoneUnknownLimitedvaries, not on a fixed pointNot reported
- ANPHormoneUnknownModeratevaries, not on a fixed pointNot reported
- ApelinMetabolicUnknownLimitedvaries, not on a fixed pointNot reported
- ApitegromabMuscle & PerformanceUnknownPreliminaryvaries, not on a fixed pointNot established (antibody; monthly intravenous dosing)
- ApraglutideHealing & RecoveryUnknownLimitedvaries, not on a fixed pointLong-acting, engineered for once-weekly subcutaneous dosing. No specific figure resolved in the sources loaded.
- ARD-101MetabolicUnknownLimitedvaries, not on a fixed pointNot meaningfully described systemically, since the molecule is designed to remain gut-restricted with minimal absorption.
- Argireline with Matrixyl and SNAP-8CosmeticUnknownLimitedvaries, not on a fixed pointNot applicable to a serum left on the skin, and no penetration or clearance study of this combination has been published.
- AshwagandhaLongevityUnknownLimitedvaries, not on a fixed pointNot reported
- AT673MetabolicUnknownLimitedvaries, not on a fixed pointNot asserted. No pharmacokinetic figure was resolved in the sources loaded.
- ATX-304MetabolicUnknownPreliminaryvaries, not on a fixed pointNot published
- AZD6234MetabolicUnknownLimitedvaries, not on a fixed pointWeekly dosing
- AzelapragMuscle & PerformanceUnknownPreliminaryvaries, not on a fixed pointNot disclosed. The company's pharmacokinetic study in older adults completed but has not been published.
- BergamotMetabolicUnknownNonevaries, not on a fixed pointNot well characterised in humans. Citrus flavanones are extensively metabolised by gut microbiota and conjugated in the liver, and plasma appearance of metabolites differs substantially between people.
- Beta-2 MicroglobulinLongevityUnknownPreliminaryvaries, not on a fixed pointNot reported
- BGE-102LongevityUnknownLimitedvaries, not on a fixed pointOnce-daily oral dosing
- BGM0504MetabolicUnknownLimitedvaries, not on a fixed pointLong enough for once-weekly subcutaneous dosing, which the phase one pharmacokinetic profile was reported to support. No specific figure is asserted here.
- BGM1812MetabolicUnknownLimitedvaries, not on a fixed pointNot reported
- BI 1820237MetabolicUnknownPreliminaryvaries, not on a fixed pointNot asserted. Single ascending dose pharmacokinetics were reported; no half-life figure was resolved in the sources loaded.
- BI 3034701MetabolicUnknownPreliminaryvaries, not on a fixed pointNot disclosed
- BIO101Muscle & PerformanceUnknownModeratevaries, not on a fixed pointNot asserted. No human half-life figure for this formulation was resolved in the sources loaded.
- BivamelagonMelanocortinUnknownLimitedvaries, not on a fixed pointNot reported
- BNP and nesiritideHormoneUnknownStrongvaries, not on a fixed pointNot reported
- BPC-157 with KPVHealing & RecoveryUnknownAnimal or lab onlyvaries, not on a fixed pointNot defined for the blend, and no pharmacokinetic study of the mixture exists. The components clear at different rates and no figure has ever been published for KPV in people.
- BPTESLongevityUnknownModeratevaries, not on a fixed pointNot reported
- BradykininHormoneUnknownLimitedvaries, not on a fixed pointNot reported
- BronchogenImmuneUnknownAnimal or lab onlyvaries, not on a fixed pointNot established
- BuntanetapNootropic & CNSUnknownLimitedvaries, not on a fixed pointOnce-daily oral dosing
- Caffeic acid phenethyl esterLongevityUnknownAnimal or lab onlyvaries, not on a fixed pointNot reported
- Carbetocin (intranasal)Nootropic & CNSUnknownModeratevaries, not on a fixed pointLonger than oxytocin, which is the stated design rationale for using this analogue rather than oxytocin. No specific human intranasal figure is asserted here because none was resolved in this pass.
- Cardiac glycosidesLongevityUnknownModeratevaries, not on a fixed pointNot reported
- CartalaxAnti-agingUnknownAnimal or lab onlyvaries, not on a fixed pointNot established. No pharmacokinetic study of this tripeptide in humans or animals was located, which is the more important fact than any number would be.
- CCL11 BlockadeLongevityUnknownPreliminaryvaries, not on a fixed pointNot reported
- CebranopadolNootropic & CNSUnknownModeratevaries, not on a fixed pointNot reported
- CerebrolysinNootropic & CNSUnknownStrongvaries, not on a fixed pointVaries by fraction
- CGRPNootropic & CNSUnknownModeratevaries, not on a fixed pointShort in circulation, consistent with its role as a locally released neuropeptide rather than a circulating hormone. No specific figure is asserted here because none was resolved in this pass. The antibodies that block it are dosed monthly or quarterly, and that long duration is a property of the antibodies, not of CGRP.
- Chemical Reprogramming CocktailsLongevityUnknownAnimal or lab onlyvaries, not on a fixed pointNot reported
- ChonlutenImmuneUnknownAnimal or lab onlyvaries, not on a fixed pointNot established
- CJC-1295 with GHRP-2Growth HormoneUnknownLimitedvaries, not on a fixed pointNot defined for the blend, and the two halves do not match. No pharmacokinetic study of the mixture exists.
- CJC-1295 with GHRP-6Growth HormoneUnknownLimitedvaries, not on a fixed pointNot defined for the blend. The published figure for the ghrelin-receptor half is in the overview above, and the mixture itself has never been measured.
- CJC-1295 with ipamorelin and GHRP-2Growth HormoneUnknownModeratevaries, not on a fixed pointNot defined for the blend, and the mismatch is the point. Two components are gone quickly while the third can persist, and the mixture has never been measured.
- ClusterinLongevityUnknownPreliminaryvaries, not on a fixed pointNot reported
- CMS-121Nootropic & CNSUnknownAnimal or lab onlyvaries, not on a fixed pointNot published
- CortagenNootropic & CNSUnknownAnimal or lab onlyvaries, not on a fixed pointNot established
- CortexinNootropic & CNSUnknownLimitedvaries, not on a fixed pointVaries (mixture)
- CotadutideMetabolicUnknownStrongvaries, not on a fixed pointNot reported
- CT-868MetabolicUnknownModeratevaries, not on a fixed pointDosed once daily in its phase two trial. No human half-life figure is asserted here; no source loaded for this entry states one.
- DanuglipronMetabolicUnknownLimitedvaries, not on a fixed pointShort (was studied as daily dosing)
- DapiglutideMetabolicUnknownLimitedvaries, not on a fixed pointLong-acting, dosed once weekly by subcutaneous injection. No specific half-life figure was resolved in the sources loaded.
- Deadpool blendHealing & RecoveryUnknownAnimal or lab onlyvaries, not on a fixed pointNot defined for the blend. The components clear at very different rates and no pharmacokinetic study of the mixture exists.
- DermorphinNootropic & CNSUnknownLimitedvaries, not on a fixed pointNot reported
- DersimelagonMelanocortinUnknownModeratevaries, not on a fixed pointOnce-daily oral dosing
- DNSP-11Nootropic & CNSUnknownAnimal or lab onlyvaries, not on a fixed pointNot reported
- DomagrozumabMuscle & PerformanceUnknownLimitedvaries, not on a fixed pointNot asserted. Serum concentrations rose with dose within each dose level; no half-life figure was resolved in the sources loaded.
- DSIP with selank and epitalonNootropic & CNSUnknownLimitedvaries, not on a fixed pointNot defined for the blend. DSIP is described as clearing rapidly and no pharmacokinetic study of the mixture exists.
- DT2216LongevityUnknownLimitedvaries, not on a fixed pointNot reported
- E5 Plasma FractionLongevityUnknownAnimal or lab onlyvaries, not on a fixed pointNot reported
- Efimosfermin alfaMetabolicUnknownModeratevaries, not on a fixed pointOnce-monthly dosing
- EfinopegdutideMetabolicUnknownModeratevaries, not on a fixed pointLong-acting, dosed once weekly by subcutaneous injection. No specific half-life figure was resolved in the sources loaded.
- EfruxiferminMetabolicUnknownModeratevaries, not on a fixed pointWeekly subcutaneous dosing
- ElecoglipronMetabolicUnknownLimitedvaries, not on a fixed pointOnce-daily oral dosing
- ElectrolytesMetabolicUnknownNonevaries, not on a fixed pointNot reported
- EloralintideMetabolicUnknownLimitedvaries, not on a fixed pointWeekly dosing (long-acting)
- EnclomipheneHormoneUnknownPreliminaryvaries, not on a fixed pointOnce-daily oral dosing
- EndolutenAnti-agingUnknownPreliminaryvaries, not on a fixed pointNot established for this product. It is a mixed preparation taken by mouth, so a single half-life would not describe it even if one had been measured.
- EnicepatideMetabolicUnknownLimitedvaries, not on a fixed pointWeekly dosing (long-acting)
- EpicatechinLongevityUnknownLimitedvaries, not on a fixed pointNot reported
- ER-100LongevityUnknownPreliminaryvaries, not on a fixed pointSingle injection; expression controlled by doxycycline course
- FGF17LongevityUnknownPreliminaryvaries, not on a fixed pointNot reported
- FGF21MetabolicUnknownModeratevaries, not on a fixed pointNot reported
- FLGR-242Muscle & PerformanceUnknownPreliminaryvaries, not on a fixed pointUnknown (no published pharmacokinetics)
- FolateMetabolicUnknownPreliminaryvaries, not on a fixed pointNot reported
- ForskolinMetabolicUnknownLimitedvaries, not on a fixed pointNot reliably established for the oral extract in humans. No adequate human pharmacokinetic study was located, and oral bioavailability is poor.
- FoselutoclaxLongevityUnknownLimitedvaries, not on a fixed pointNot established (intravitreal; durable local effect)
- GB-115Nootropic & CNSUnknownAnimal or lab onlyvaries, not on a fixed pointNot published
- GDF11Anti-agingUnknownPreliminaryvaries, not on a fixed pointCirculates as a latent complex. No verified circulating half-life is asserted here.
- GDF15MetabolicUnknownModeratevaries, not on a fixed pointNot reported
- GHK-Cu with zinc thymulinCosmeticUnknownLimitedvaries, not on a fixed pointNot applicable to a serum left on the scalp, and no absorption or clearance study of either component has been published.
- GlepaglutideMetabolicUnknownModeratevaries, not on a fixed pointNot reported
- GLOW blendCosmeticUnknownLimitedvaries, not on a fixed pointNot defined for the blend. No pharmacokinetic study of the mixture exists.
- GLOW capsulesCosmeticUnknownLimitedvaries, not on a fixed pointNot defined. No absorption or clearance study of these peptides taken by mouth has been published.
- Gpld1LongevityUnknownPreliminaryvaries, not on a fixed pointNot reported
- Green tea extractLongevityUnknownModeratevaries, not on a fixed pointNot reported
- GUBamyMetabolicUnknownPreliminaryvaries, not on a fixed pointNot reported
- GW0742MetabolicUnknownAnimal or lab onlyvaries, not on a fixed pointNot established in humans; no human pharmacokinetic study of this compound exists.
- GYM329Muscle & PerformanceUnknownPreliminaryvaries, not on a fixed pointNot asserted. No human half-life figure was resolved in the sources loaded.
- HalofuginoneLongevityUnknownPreliminaryvaries, not on a fixed pointNot reported
- HEC88473MetabolicUnknownLimitedvaries, not on a fixed pointNot asserted. A single ascending dose study characterised pharmacokinetics; no half-life figure was resolved in the sources loaded.
- HRS-7535MetabolicUnknownModeratevaries, not on a fixed pointOnce-daily oral dosing
- IcotrokinraImmuneUnknownModeratevaries, not on a fixed pointOnce daily dosing
- InulinMetabolicUnknownLimitedvaries, not on a fixed pointNot applicable. Inulin is not absorbed, so it has no plasma half-life; its effects follow colonic fermentation and bowel transit rather than drug kinetics.
- IO102-IO103ImmuneUnknownModeratevaries, not on a fixed pointNot reported
- IrisinMetabolicUnknownLimitedvaries, not on a fixed pointNot reported
- IronMetabolicUnknownPreliminaryvaries, not on a fixed pointNot reported
- KlothoLongevityUnknownPreliminaryvaries, not on a fixed pointEndogenous protein; therapeutic forms not yet defined in humans
- KLOW blendHealing & RecoveryUnknownLimitedvaries, not on a fixed pointNot defined for the blend, and the components differ. No pharmacokinetic study of the mixture exists.
- LandogrozumabMuscle & PerformanceUnknownModeratevaries, not on a fixed pointNot asserted. No half-life figure was resolved in the sources loaded. Dosing in the falls trial was monthly subcutaneous injection.
- LanifibranorMetabolicUnknownLimitedvaries, not on a fixed pointOnce-daily oral dosing
- LinaclotideHealing & RecoveryUnknownLimitedvaries, not on a fixed pointNot meaningfully described systemically, because absorption is minimal by design. The peptide and its active metabolite act locally in the gut lumen and are degraded there.
- LivagenLongevityUnknownAnimal or lab onlyvaries, not on a fixed pointNot established
- LorecivivintHealing & RecoveryUnknownStrongvaries, not on a fixed pointOne to two intra-articular injections per year
- LotiglipronMetabolicUnknownPreliminaryvaries, not on a fixed pointDesigned for once-daily oral dosing. No specific half-life figure was resolved in the sources loaded.
- LOY-002LongevityUnknownAnimal or lab onlyvaries, not on a fixed pointOnce-daily oral dosing
- MagnesiumLongevityUnknownLimitedvaries, not on a fixed pointNot meaningfully described by a half-life. Magnesium is not stored for later use in the way fat-soluble vitamins are, so absorption above current need is followed by increased urinary excretion. Renal handling, not plasma clearance, governs status.
- Melanotan II with PT-141MelanocortinUnknownLimitedvaries, not on a fixed pointNot defined for the pairing. Both are used episodically rather than on a fixed schedule, and no pharmacokinetic study of the two together exists.
- MelatoninLongevityUnknownNonevaries, not on a fixed pointNot reported
- MelittinHealing & RecoveryUnknownModeratevaries, not on a fixed pointNot reported
- Metformin plus rapamycinLongevityUnknownPreliminaryvaries, not on a fixed pointNot reported
- Mitochondrial+ blendLongevityUnknownPreliminaryvaries, not on a fixed pointNot defined for the blend. Three components with different clearance and no pharmacokinetic study of the mixture.
- MitoglitazoneLongevityUnknownModeratevaries, not on a fixed pointNot reported
- MitoQAntioxidantUnknownLimitedvaries, not on a fixed pointNot asserted. No reliable human half-life figure was resolved in the sources loaded. Mitochondrial accumulation means tissue kinetics differ substantially from plasma kinetics.
- MK-677 with ipamorelinGrowth HormoneUnknownModeratevaries, not on a fixed pointNot defined for the pairing. One component persists far longer than the other, which is why no single schedule fits both, and the pairing has never been measured.
- MonlunabantMetabolicUnknownLimitedvaries, not on a fixed pointOnce-daily oral dosing
- MOTS-c with SS-31LongevityUnknownPreliminaryvaries, not on a fixed pointNot defined for the blend. No pharmacokinetic study of the combination exists and neither component has an established dosing interval outside a trial protocol.
- MyostatinMuscle & PerformanceUnknownModeratevaries, not on a fixed pointCirculates as a latent complex; no single agreed circulating half-life is asserted here.
- N-Acetyl Semax AmidateNootropic & CNSUnknownAnimal or lab onlyvaries, not on a fixed pointNot established
- NAD+ with glutathioneLongevityUnknownLimitedvaries, not on a fixed pointNot defined for the protocol. Both components turn over rapidly in plasma and neither has an established intravenous dosing interval for any longevity indication.
- NavepegritideHormoneUnknownPreliminaryvaries, not on a fixed pointWeekly dosing (prodrug release)
- NavitoclaxLongevityUnknownModeratevaries, not on a fixed pointNot reported
- NDGALongevityUnknownAnimal or lab onlyvaries, not on a fixed pointNot asserted for the mouse dietary regimen. Fed continuously in the diet in the lifespan studies.
- Nesfatin-1MetabolicUnknownAnimal or lab onlyvaries, not on a fixed pointNot established. No human pharmacokinetic study exists, because this peptide has never been administered to a human being in any published study.
- NimacimabMetabolicUnknownLimitedvaries, not on a fixed pointWeekly dosing (antibody)
- NNC0165-1875MetabolicUnknownModeratevaries, not on a fixed pointLong-acting, engineered for weekly subcutaneous dosing. No specific half-life figure was resolved in the sources loaded.
- NNC0480-0389MetabolicUnknownModeratevaries, not on a fixed pointLong-acting, designed for weekly subcutaneous dosing alongside semaglutide. No specific figure resolved in the sources loaded.
- NNZ-2591Nootropic & CNSUnknownLimitedvaries, not on a fixed pointOral, twice daily
- NoiiglutideMetabolicUnknownLimitedvaries, not on a fixed pointLong-acting, engineered for infrequent subcutaneous dosing. No specific figure was resolved in the sources loaded.
- NomlabofuspNootropic & CNSUnknownLimitedvaries, not on a fixed pointNot reported
- NRHLongevityUnknownLimitedvaries, not on a fixed pointNo human pharmacokinetic study has been published, so no half-life in people can be stated. The mouse work used intraperitoneal injection and oral gavage and reported tissue NAD rather than compound clearance.
- o-VanillinAnti-agingUnknownAnimal or lab onlyvaries, not on a fixed pointNot established. No pharmacokinetic study in people has been published, and the published work uses direct application to tissue or oral dosing in mice rather than measured systemic exposure in humans.
- OSK Partial ReprogrammingLongevityUnknownPreliminaryvaries, not on a fixed pointNot reported
- OSKM Cyclic Partial ReprogrammingLongevityUnknownAnimal or lab onlyvaries, not on a fixed pointNot reported
- OsteocalcinHormoneUnknownPreliminaryvaries, not on a fixed pointNot stated here. Circulating osteocalcin is cleared quickly and the assays used across the literature measure different fragments, so a single figure would be misleading.
- OvagenAnti-agingUnknownAnimal or lab onlyvaries, not on a fixed pointNot established, and no pharmacokinetic work exists for this product under any name.
- OxaloacetateLongevityUnknownModeratevaries, not on a fixed pointVery short and poorly characterised. Free oxaloacetate is chemically unstable, which is why supplements use a stabilised anhydrous form, and the Alzheimer's study did not find consistent blood level changes with dose.
- PancragenMetabolicUnknownPreliminaryvaries, not on a fixed pointNot established
- PDA with TB-500Healing & RecoveryUnknownAnimal or lab onlyvaries, not on a fixed pointNot defined for the blend. Nothing has been published for the arginate salt, for the fragment, or for the mixture.
- PEG-loxenatideMetabolicUnknownModeratevaries, not on a fixed pointLong enough for once-weekly subcutaneous dosing. No specific human figure is asserted here; no source loaded states one in the records resolved for this entry.
- PEG-MGFMuscle & PerformanceUnknownPreliminaryvaries, not on a fixed pointExtended by pegylation
- PemvidutideMetabolicUnknownLimitedvaries, not on a fixed pointSupports weekly dosing
- Pentadeca ArginateHealing & RecoveryUnknownAnimal or lab onlyvaries, not on a fixed pointNo human pharmacokinetics for either salt form
- Peptide YYMetabolicUnknownLimitedvaries, not on a fixed pointNot reported
- PetrelintideMetabolicUnknownModeratevaries, not on a fixed pointSupports weekly dosing
- PiperlongumineLongevityUnknownAnimal or lab onlyvaries, not on a fixed pointNot reported
- PL8177MelanocortinUnknownPreliminaryvaries, not on a fixed pointOral, gut-targeted
- Plasma DilutionLongevityUnknownLimitedvaries, not on a fixed pointNot reported
- Platelet Factor 4LongevityUnknownAnimal or lab onlyvaries, not on a fixed pointNot reported
- PlecanatideHealing & RecoveryUnknownStrongvaries, not on a fixed pointNot calculable. The label states that a half-life could not be determined, because systemic absorption is minimal and the drug acts on receptors facing into the gut lumen.
- PNC-27ImmuneUnknownAnimal or lab onlyvaries, not on a fixed pointNot established
- PQQAntioxidantUnknownModeratevaries, not on a fixed pointNot characterised here. We could not resolve a primary human pharmacokinetic study, so no figure is stated.
- Procyanidin C1LongevityUnknownAnimal or lab onlyvaries, not on a fixed pointNot reported
- ProtandimAntioxidantUnknownAnimal or lab onlyvaries, not on a fixed pointNot meaningfully described. It is a mixture of botanical extracts with differing kinetics rather than a single compound.
- PsylliumMetabolicUnknownNonevaries, not on a fixed pointNot reported
- PT-141 with oxytocinMelanocortinUnknownLimitedvaries, not on a fixed pointNot defined for the blend. Oxytocin disappears from plasma very quickly, the melanocortin component is used episodically, and the mixture has never been measured.
- PterostilbeneLongevityUnknownLimitedvaries, not on a fixed pointNot established in humans. No human pharmacokinetic study was located for this entry; the comparative absorption work is in rats.
- Quad healing blendHealing & RecoveryUnknownLimitedvaries, not on a fixed pointNot defined for the blend. Four components with different clearance and no pharmacokinetic study of the mixture.
- Rapamycin plus acarboseLongevityUnknownAnimal or lab onlyvaries, not on a fixed pointNot reported
- RapastinelNootropic & CNSUnknownStrongvaries, not on a fixed pointNot reported
- RemternetugNootropic & CNSUnknownPreliminaryvaries, not on a fixed pointSubcutaneous dosing; interval per protocol
- Retatrutide with cagrilintideMetabolicUnknownStrongvaries, not on a fixed pointNot defined for the blend. Both components support weekly dosing individually and no pharmacokinetic study of the mixture exists.
- RibupatideMetabolicUnknownLimitedvaries, not on a fixed pointWeekly dosing (long-acting)
- RisuteganibHealing & RecoveryUnknownModeratevaries, not on a fixed pointNot reported
- RTB101LongevityUnknownModeratevaries, not on a fixed pointNot asserted. No reliable half-life figure at the low geroscience doses was resolved in the sources loaded.
- RTR242Nootropic & CNSUnknownLimitedvaries, not on a fixed pointOral; not disclosed
- SeleniumLongevityUnknownModeratevaries, not on a fixed pointNot reported
- Semaglutide with B12MetabolicUnknownLimitedvaries, not on a fixed pointNot defined for the mixture. The incretin component supports weekly dosing and the vitamin behaves as a vitamin, with no pharmacokinetic study of the combined preparation.
- Semaglutide with BPC-157MetabolicUnknownLimitedvaries, not on a fixed pointNot defined for the pairing, and the mismatch is large. One component persists across the full interval and the other disappears almost at once.
- Semaglutide with cagrilintideMetabolicUnknownStrongvaries, not on a fixed pointNot defined for a grey-market mixture. Both components support once-weekly dosing individually and the trialled co-formulation is given weekly.
- Semax with selank and dihexaNootropic & CNSUnknownLimitedvaries, not on a fixed pointNot defined for the stack, and no pharmacokinetic study of the combination exists. The two Russian peptides are typically dosed intranasally rather than injected.
- Senolytic CAR T cellsImmuneUnknownAnimal or lab onlyvaries, not on a fixed pointNot applicable in the usual sense. This is a living cell product that expands on meeting its target and persists, so exposure is governed by the survival of the engineered cells rather than by drug clearance.
- Senolytic vaccine (anti-GPNMB)ImmuneUnknownAnimal or lab onlyvaries, not on a fixed pointNot applicable. A vaccine is dosed as a course and its effect depends on the immune response it raises, not on clearance of the injected material.
- Sermorelin with GHRP-2 and GHRP-6Growth HormoneUnknownLimitedvaries, not on a fixed pointNot defined for the blend. All three components clear quickly, and the published figure for the growth hormone releasing peptide component is in the overview above.
- Sermorelin with ipamorelinGrowth HormoneUnknownModeratevaries, not on a fixed pointNot defined for the blend, and both halves are short acting, which is why the dose is given at bedtime. No pharmacokinetic study of the mixture exists.
- SG1002LongevityUnknownAnimal or lab onlyvaries, not on a fixed pointNot asserted. No half-life figure for the prodrug or for the resulting sulfide exposure was resolved in the sources loaded.
- SHLP2LongevityUnknownPreliminaryvaries, not on a fixed pointNot established in humans. No pharmacokinetic study exists because the peptide has never been dosed in a person.
- SkQ1AntioxidantUnknownPreliminaryvaries, not on a fixed pointNot established systemically
- SRK-439Muscle & PerformanceUnknownAnimal or lab onlyvaries, not on a fixed pointSubcutaneous; interval not disclosed
- SRT2104LongevityUnknownLimitedvaries, not on a fixed pointNot asserted. No reliable half-life figure was resolved in the sources loaded.
- SS-20AntioxidantUnknownAnimal or lab onlyvaries, not on a fixed pointNot established. No pharmacokinetic study in humans exists, and the animal work used pretreatment or continuous infusion schedules rather than single-dose kinetics.
- Taldefgrobep alfaMuscle & PerformanceUnknownPreliminaryvaries, not on a fixed pointWeekly or monthly subcutaneous dosing
- TaspoglutideMetabolicUnknownStrongvaries, not on a fixed pointNot reported
- TB-500Healing & RecoveryUnknownPreliminaryvaries, not on a fixed pointNot established in humans
- TelaglenastatLongevityUnknownModeratevaries, not on a fixed pointNot reported
- TERN-601MetabolicUnknownLimitedvaries, not on a fixed pointDesigned for once-daily oral dosing. No specific figure was resolved in the sources loaded.
- Therapeutic Plasma ExchangeLongevityUnknownModeratevaries, not on a fixed pointNot reported
- Thymalin with epitalonLongevityUnknownStrongvaries, not on a fixed pointNot defined. No pharmacokinetic study of either preparation has been published in a Western journal.
- Thymosin alpha-1 with KPV and LL-37ImmuneUnknownStrongvaries, not on a fixed pointNot defined for the blend. No pharmacokinetic study of the mixture exists and the components differ in clearance.
- TIMP2LongevityUnknownPreliminaryvaries, not on a fixed pointNot reported
- Tirzepatide with B12MetabolicUnknownLimitedvaries, not on a fixed pointNot defined for the mixture. The incretin component supports weekly dosing; no pharmacokinetic study of the premix has been published, and the impurity's behaviour is unknown.
- Tirzepatide with BPC-157MetabolicUnknownLimitedvaries, not on a fixed pointNot defined for the pairing. One component persists across the full interval and the other disappears almost at once, which is why no shared schedule exists.
- TrevogrumabMuscle & PerformanceUnknownLimitedvaries, not on a fixed pointAntibody dosing per trial protocol
- TrigonellineLongevityUnknownAnimal or lab onlyvaries, not on a fixed pointNot established
- TrodusquemineMetabolicUnknownAnimal or lab onlyvaries, not on a fixed pointNot established
- TrontinemabNootropic & CNSUnknownLimitedvaries, not on a fixed pointNot established (antibody; monthly then quarterly intravenous dosing)
- TUDCALongevityUnknownLimitedvaries, not on a fixed pointNot established for supplemental dosing. Bile acids recirculate between gut and liver many times over, so a single plasma figure does not describe exposure.
- TurkesteroneMuscle & PerformanceUnknownNonevaries, not on a fixed pointNot asserted. No human pharmacokinetic data for turkesterone was resolved in the sources loaded.
- UBT251MetabolicUnknownLimitedvaries, not on a fixed pointWeekly dosing (long-acting)
- UBX0101LongevityUnknownModeratevaries, not on a fixed pointNot reported
- Urolithin BMuscle & PerformanceUnknownLimitedvaries, not on a fixed pointNot established in humans. No human pharmacokinetic study of administered urolithin B exists.
- Ursolic acidMuscle & PerformanceUnknownLimitedvaries, not on a fixed pointNot reliably established in humans. Oral bioavailability is low and no human pharmacokinetic study adequate to define a half-life was located.
- Vitamin K2LongevityUnknownPreliminaryvaries, not on a fixed pointNot reported
- VK2735MetabolicUnknownStrongvaries, not on a fixed pointSupports weekly dosing (injectable)
- Young Plasma InfusionLongevityUnknownLimitedvaries, not on a fixed pointNot reported
- ZincLongevityUnknownNonevaries, not on a fixed pointNot reported
- Zinc-L-carnosineHealing & RecoveryUnknownLimitedvaries, not on a fixed pointNot meaningfully described as a chelate, because its intended action is local adhesion to mucosa and local zinc release rather than systemic exposure.
- Zoledronic acidLongevityUnknownStrongvaries, not on a fixed pointPlasma clearance is rapid and multiphasic, but the drug binds to bone mineral and is released slowly over years as bone turns over, so no single plasma figure describes its duration of action. This is why it is dosed once a year.
453 of 453 compounds shown ยท 217 with no reported half-life.
Frequently asked questions
What is a peptide's half-life?
Half-life is the time it takes for the amount of a compound in the body to drop by half. After about four to five half-lives, roughly 94 to 97 percent is gone. So half-life is a useful guide to how long a compound stays active.
Why do half-lives matter?
Half-life shapes how a compound acts over time. A very short half-life means the body clears it fast. A long half-life means it hangs around for days. This is general information about how drugs move through the body, not dosing advice.
Are these half-lives exact?
No. Half-lives change with the product, how it is taken, and the person. Some values are rough, or given as ranges. The numbers here come from published values and are rounded so you can compare them.
What does it mean when a half-life is not reported?
Some compounds have no published half-life, or the record only describes it in words, with no number. Those are shown as unknown. We do not guess or put them on the scale.
Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use. The Longevity Archive does not provide dosing guidance.